CLLResearch at Yahoo! Groups http://health.groups.yahoo.com/group/CLLResearch/ CLL-Researchand Advocacy Histone Deacetylase Inhibitors in Cancer Therapy Sun, 08 Nov 2009 22:40:49 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12685 http://health.groups.yahoo.com/group/CLLResearch/message/12685 Originally published as JCO Early Release 10.1200/JCO.2009.22.1291 on October 13 2009 Journal of Clinical Oncology, Vol 27, No 32 (November 10), 2009: pp. Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed Sun, 08 Nov 2009 22:37:23 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12684 http://health.groups.yahoo.com/group/CLLResearch/message/12684 Originally published as JCO Early Release 10.1200/JCO.2008.21.1169 on October 5 2009 Journal of Clinical Oncology, Vol 27, No 32 (November 10), 2009: pp. Differential genome-wide array-based methylation profiles in prognos Sun, 08 Nov 2009 22:33:41 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12683 http://health.groups.yahoo.com/group/CLLResearch/message/12683 Blood First Edition Paper, prepublished online November 6, 2009; DOI 10.1182/blood-2009-07-232868. Differential genome-wide array-based methylation profiles in Personalized Oncology? Sun, 08 Nov 2009 22:05:01 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12682 http://health.groups.yahoo.com/group/CLLResearch/message/12682 This enlightening article by Ralph Moss is especially relevant to blood cancers. (andy) Personalized Oncology? Sunday, 08 November 2009 The latest buzzword in Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphoc Sat, 07 Nov 2009 01:10:25 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12681 http://health.groups.yahoo.com/group/CLLResearch/message/12681 Blood, 5 November 2009, Vol. 114, No. 19, pp. 4150-4157. Prepublished online as a Blood First Edition Paper on September 4, 2009; DOI CT-011 antibody - targets Programmed Death-1 receptor Fri, 06 Nov 2009 14:38:28 GMT KarlS@... http://health.groups.yahoo.com/group/CLLResearch/message/12680 http://health.groups.yahoo.com/group/CLLResearch/message/12680 Greetings, The shortest distance between two points ... or the clinical use of improved agents against lymphoma is the efficient enrollment in clinical trials The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to V Fri, 06 Nov 2009 00:06:32 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12679 http://health.groups.yahoo.com/group/CLLResearch/message/12679 Published online October 19, 2009 The Journal of Immunology, 2009, 183, 6145 -6150 doi:10.4049/jimmunol.0901596 The Proteasome Inhibitor Bortezomib Enhances OT: possible breakthrough for gene therapy treating genetic disorder Thu, 05 Nov 2009 21:21:18 GMT KarlS@... http://health.groups.yahoo.com/group/CLLResearch/message/12678 http://health.groups.yahoo.com/group/CLLResearch/message/12678 Rare Disease Treated Using Gene Therapy http://www.npr.org/templates/story/story.php?storyId=120118988 Not related to lymphoma directly, but if safety is Studies: Azacytidine (an epigenetic agent) Wed, 04 Nov 2009 19:44:29 GMT KarlS@... http://health.groups.yahoo.com/group/CLLResearch/message/12677 http://health.groups.yahoo.com/group/CLLResearch/message/12677 Azacytidine is a so-called epigenetic agent, which might "activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect." The A phase I/II dose escalation study of apolizumab (Hu1D10) using a st Tue, 03 Nov 2009 21:53:12 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12676 http://health.groups.yahoo.com/group/CLLResearch/message/12676 A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Infectious complications in patients with chronic lymphocytic leukem Tue, 03 Nov 2009 21:48:39 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12675 http://health.groups.yahoo.com/group/CLLResearch/message/12675 Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. VA Morrison Clin Fludarabine followed by alemtuzumab consolidation for previously unt Tue, 03 Nov 2009 21:39:55 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12674 http://health.groups.yahoo.com/group/CLLResearch/message/12674 Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study A Genomic Approach to Improve Prognosis and Predict Therapeutic Resp Tue, 03 Nov 2009 21:34:25 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12673 http://health.groups.yahoo.com/group/CLLResearch/message/12673 A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia. Daphne R Friedman, J Brice Weinberg, William T Barry, Pbox-15 kills cancer cells without harming healthy cells Tue, 03 Nov 2009 18:19:24 GMT Andrew Gach http://health.groups.yahoo.com/group/CLLResearch/message/12672 http://health.groups.yahoo.com/group/CLLResearch/message/12672 Pbox-15 kills cancer cells without harming healthy cells Pbox-15, a potential new drug compound discovered by Irish clinical scientists, is found to be highly L&M conf: the case for and against PET Mon, 02 Nov 2009 14:40:27 GMT KarlS@... http://health.groups.yahoo.com/group/CLLResearch/message/12671 http://health.groups.yahoo.com/group/CLLResearch/message/12671 Summary taken from notes (could have errors) CLINICAL UTILITY OF PET: * Reproducibility (No) * Improves care (Sometimes) * Improves outcomes (Not known